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Abstract:  
Very low calorie diets (VLCDs) are an effective means by which to induce clinically 
significant weight loss. However, their acceptance by health care practitioners and 
the public is generally lower than that for other non-surgical weight loss methods. 
Whilst there is currently little evidence to suggest any detriment to hepatic and renal 
health, data assessing these factors remain limited. We carried out a systematic 
review of the literature for randomised controlled trials which had a VLCD component 
and reporting outcomes for hepatic and renal health, published between January 
1980 and December 2012. Cochrane criteria were followed and eight out of 196 
potential articles met the inclusion criteria. A total of 548 participants were recruited 
between the 8 studies. All 8 studies reported significant weight loss following the 
VLCD. Changes in hepatic and renal outcomes were variable but generally led to 
either no change or improvements in either of these. Due to the heterogeneous 
nature of the quality and methodology of the studies included, the effect of VLCDs on 
hepatic and renal outcomes remain unclear at this stage.   Further standardised 
research is therefore required to fully assess the impact of VLCDs on these outcome 
measures to better guide clinical practice. 
 
Introduction: 
The prevalence of overweight and obesity is increasing globally and effective weight 
loss treatment is of great importance from both a health and socioeconomic 
perspective Wang et al.1 Very low calorie diets (VLCDs) are an effective means by 
which to induce a clinically significant weight loss.2 However their acceptance by 
health care practitioners and the public in general is much lower than that for other 
non-surgical weight loss methods.  This is likely to be due to the adverse effects of 
nutritionally insufficient VLCDs in the 1970s which resulted in a number of deaths 
due to vitamin and mineral deficiencies and poor quality or inadequate amounts of 
protein.3,4 These are however completely different from the nutritionally replete 
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variants of modern day VLCDs and despite the fact that the fast weight loss seen in 
followers of a VLCD is generally perpetuated as being unsafe, there is no convincing 
evidence to suggest that this is the case.  Indeed, the European Food Safety 
Authority (EFSA) has approved a health claim with regards to the efficacy of VLCDs 
on weight loss in a target population of obese adults.5 
  
A VLCD is defined as a diet of <800 kcal/day6 and there are many commercially 
available variants which provide energy intakes between 300-800 kcal/day.  
There is sufficient evidence in the literature to ensure the safe use of VLCDs in 
healthy overweight and obese patients in the short-term7,8 however, there remains 
limited evidence on the effects of VLCDs on specific disease groups over this same 
period of time.  This is likely to in part be due to the strict protocols and monitoring 
which are advised with this type of dietary approach to weight loss.  Although 
evidence for the benefits of VLCDs is mounting in certain groups of individuals at 
higher cardiovascular risk, for example those with type 2 diabetes mellitus (T2DM), 
9,10 there is little evidence of outcomes in other obesity-related secondary diseases, 
such as non-alcoholic fatty liver disease (NAFLD).  In a recent review, Mulholland et 
al2 investigating long-term (>12 month) randomised control trials of VLCD identified 
only 2 studies which evaluated effect on liver and kidney function .11,12 One paper,11 
described that at 2 years follow-up, there were no significant changes in liver 
transaminases.  The other paper,12 reported both statistically and biologically 
significant improvements in both hepatic and renal health including changes in 
alanine aminotransferase, alkaline phosphatase, ү-Glutamyl transferase, creatinine, 
eGFR and urea.  The observed changes in liver enzymes indicated an improvement 
in hepatic steatosis and an improvement in biochemical markers associated with 
renal and hepatic pathology.  
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Furthermore, a recent study by Lim et al13 reported that in patients with T2DM who 
followed a VLCD, the resulting acute negative energy balance reversed T2DM by 
normalising both insulin sensitivity and beta cell function. The authors suggested this 
observation was due to the reduction of fat in the liver and pancreas.  These results 
are in keeping with our previous findings which demonstrated improvements in liver 
enzymes following a VLCD.12 
 
Whilst there is currently little evidence to suggest any detriment to liver or kidney 
health, data assessing these factors remain limited. Thus, we aim to carry out a 
systematic review of the literature for studies using a VLCD and reporting outcomes 
for liver and kidney health, published between January 1980 and December 2012.  
 
Methods:  
The protocol used for this systematic review follows the methods recommended by 
the Cochrane Collaboration.14 Further details of the approach are described below.  
Inclusion Criteria 
This review is intended to assess the literature in this field. Studies from January 
1980 to December 2012 were evaluated. Studies prior to 1980 were not included due 
to health concerns associated with formulations of VLCDs in the1970s.3,4 
Interventions where the participants had a mean or median BMI of ≥28 kg/m2 were 
included, and restricted to studies in adults only (18 years and over).  Only 
randomised controlled trials with a VLCD component were evaluated. The variation 
of time on diet using active intervention, follow up and different follow up treatments 
was recorded and accounted for where possible. 
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Types of Intervention 
The focus of this review was to examine the effect of VLCDs on hepatic and renal 
outcomes.  The types of dietary interventions evaluated were VLCDs also known as 
very low energy diets defined as a dietary intake of 800kcal/day or less.  
Outcome Measures  
Weight loss was the main outcome assessed from the studies included in the review. 
With regard to hepatic or renal status, the following outcomes were also included: 
• Liver enzymes (alanine aminotransferase (ALT), alkaline phosphatase (ALKP), 
aspartate transaminase (AST), gamma-glutamyl transpeptidase (GGT), albumin). 
• Electrolytes, urea and kidney function (sodium, potassium, chloride, 
creatinine, and estimated glomerular filtration rate (eGFR)) 
• Non-alcoholic fatty liver disease (NAFLD) 
Search Strategy for the Identification of Included Studies 
This systematic review was restricted to studies where the full study report was 
available. A search strategy on MEDLINE was applied to identify as many studies 
evaluating dietary interventions using VLCDs as possible and which were relevant to 
hepatic and renal status. The search strategy incorporated the following terms “very 
low calorie/energy diet”. Reference lists of included studies and reviews were 
searched and authors contacted for further details of their trials. 
Quality Assessment of Studies 
The protocol used for the quality assessment follows the methods recommended by 
the Avenell et al.15  Studies were classified as having either a low risk of bias (A), an 
unclear risk of bias (B), or a high risk of bias (C). Subset “I” suggests that a 
description was provided while subset “II” suggests that no description was provided. 
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Full copies of studies were assessed by 2 researchers for methodological quality. 
The researchers were not blinded to author, journal or institution. Differences of 
opinion were resolved by discussion. Trial quality was assessed, including whether or 
not the analysis was undertaken on an intention to treat basis.  
 
Identified Studies 
A total of 8 out of 196 articles met the inclusion criteria and were included in the 
systematic review. Reasons for the exclusion of these studies is summarised in 
Figure 1. 
Results: 
Study Characteristics 
A total of 548 participants were recruited betweem the 8 studies included in this 
systematic review. There was a large amount of heterogeneity in study design for the 
papers meeting the inclusion criteria.  The studies included ranged from 8 weeks16 to 
2 years11 in duration. Periods of VLCD ranged from 25 days11 to 9 months.12  In the 
follow-up phase, different studies incorporated aspects of behaviour modification,11 
reduced calorie intake,17-19 or medication (acarbose) (Table 1).20   
  
All of the studies were designed to reduce weight or prevent weight gain and also 
examined hepatic and renal outcomes. Results for all the studies are summarised in 
Table 1. 
 
Quality Assessment 
Table 2 displays the quality assessment of reported studies. All of the studies were 
randomised but allocation description was generally not provided with the exception 
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of one paper21 where the method of concealment had a real chance of disclosure of 
assignment prior to formal trial entry. Four studies11,18-20 clearly stated numbers and 
reasons for withdrawal from the study, while two studies12,21 only provided numbers 
and two studies16,17 made no mention of dropouts. Three studies analysed the data 
with intention to treat, 12,20,21 while three16,17,19 may have, but the methods of analysis 
was unclear and two studies11,18 presented data for completers only. Participants as 
well as healthcare providers were blinded to the treatment in two studies (test 
emulsion,18 acarbose20). Participants were not blinded in the other six studies and it 
was unclear if the healthcare providers or the outcome assessors were blinded to 
treatment status.   
 
Weight change 
All 8 of the studies resulted in significant weight loss following the VLCD period 
(Table 2). Where weight change was reported after a follow up period, the 
implementation of either a reduced calorie diet,17 regular support through intensive or 
less intensive behaviour modification therapy,11 meal replacement once a day18 and 
ongoing use of VLCD12 resulted in the maintenance of significant weight loss 
compared with baseline. Although no values for weight change were provided, 
Hauner et al20 stated that the use of acarbose resulted in individuals remaining 
weight stable for the weeks following the VLCD (Table 2). 
 
Hepatic outcomes 
Table 3 displays the results for different hepatic outcomes reported in 3 of the 
studies. Arai et al16 observed an improvement in AST and ALT following the VLCD. 
Rolland et al12 also reported an improvement in ALT, as well as in ALKP, GGT and 
albumin following the VLCD period.  Melin et al11 provided baseline values but only 
anecdotally reported no changes in liver transaminases. 
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Two other studies reported anecdotal results (i.e. no values were presented) of 
changes in hepatic outcomes. Olsson et al18 reported that ALT levels increased 
significantly during the weight reduction phase but were normalised during the 12 
week weight maintenance phase, whereas Hauner et al20 reported that no changes 
were observed in serum transaminases in participants undergoing a VLCD followed 
by the use of acarbose. 
 
Only one study investigated the effect of VLCDs on NAFLD. In the study by Lin et 
al21, 41 participants with NAFLD were placed on a 450 kcal/d VLCD for 12 weeks.  In 
this group, a 41.5% improvement rate in NAFLD was reported where 5 of the 41 
participants no longer had NAFLD and others had improvements in severity; however 
of the 5 participants in this group who did not have NAFLD at the beginning of the 
intervention, 2 had developed NAFLD by the end of the intervention. Lin et al21 also 
had participants on an 800 kcal/d VLCD. In this latter group, they observed a 50% 
improvement rate where of the 42 participants who initially presented with NAFLD, 10 
no longer had NAFLD; and of the 5 participants who did not have NAFLD at baseline, 
none developed it.  
 
Renal outcomes 
Table 4 displays the results for renal outcomes for the only paper12 which provided 
values for changes in renal function. The results demonstrated an improvement in 
creatinine, urea and eGFR urea levels in response to a VLCD.  
 
Two other studies reported anecdotal outcomes for renal function. Doherty et al,17 
stated that there were no significant changes in potassium, sodium or chloride 
observed at 45 weeks in response to a VLCD followed by a balanced deficit diet. 
Similarly, Ryttig and Rössner20 reported that there were no significant changes in 
serum electrolytes (sodium, potassium) at the end of the 12 weeks of VLCD and that 
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there were no significant changes during the weight maintenance period between the 
two groups (balanced hypocaloric diet with or without a meal replacement 
component).  
 
 
Discussion:  
As expected from previous studies, the VLCD interventions resulted in significant 
weight loss. Changes in hepatic and renal outcomes resulting from the weight loss 
achieved using the VLCDs were variable but generally led to either no change or an 
improvement in hepatic and renal health. This may be due to the fact that theses 
studies measuring kidney and liver outcomes only included adults with normal kidney 
and liver function with the exception of NAFLD.  
 
The outcomes in terms of hepatic function were improved in some studies, remained 
the same in others, and initially increased during the VLCD phase but normalised 
thereafter in one study. The inconsistencies between these studies are likely to be 
due to a combination of things including the different lengths of treatment, different 
sampling times as well as different weight maintenance approaches. However, these 
studies certainly did not demonstrate any negative outcomes for hepatic health in 
response to a VLCD and subsequent follow-up. On the contrary, when looking at the 
outcomes for NAFLD, the effect of the weight loss achieved by the VLCD resulted in 
important improvements in NAFLD most likely due to the associated decrease in 
visceral adiposity. 22 These results are supported by Rolland et al12 who suggest that 
changes in liver enzymes may indicate an improvement in hepatic steatosis. Several 
other studies have also suggested beneficial effects of weight loss on liver size and 
adiposity.  Colles et al,23 observed that during a 12 week VLCD most of the reduction 
in liver size occurred in the first 2 weeks of weight loss, likely due to the low 
carbohydrate content of the diet resulting in the depletion of liver glycogen and bound 
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water.24 Favourable changes were also observed for a range of biochemical and 
clinical tests (significant decrease in ALKP, bilirubin, ALT, GGT). Andersen et al25 
investigated the effects of weight loss induced by a VLCD on liver morphology and 
function in morbidly obese, but otherwise healthy individuals. They observed a 
marked improvement in hepatic health which correlated with the reduction of weight. 
However, they also observed that 24% of the patients developed a slight portal 
inflammation as well as a slight portal fibrosis in 12% of patients. They did not find 
predictors (morphological or biochemical) for these changes and hypothesised that a 
fast mobilisation of intracellular triacylglycerols and subsequent secretion of fatty 
acids had induced a portal inflammation which in turn led to fibrosis. They proposed 
that a rapid mobilisation of intra- and extra- hepatic fat stores may present a 
hepatotoxic factor common to all weight loss treatments that induce rapid weight 
loss. Based on their observations, they postulated that to avoid development of portal 
fibrosis during treatment with VLCD, a weight loss slower than 1.6kg/week should be 
recommended.  
 
The issue of development of fibrosis in the Andersen study25 should not be confused 
with the development of fibrosis observed in individuals following bariatric surgery, 
another approach which induces rapid weight loss. Several studies have reported 
improvements in liver biochemical and histological outcomes26-28 but some do 
express concern that rapid weight loss may be a causative factor in the occurrence of 
fibrosis that is observed.27-29 However, as Kral et al28 suggest, this may be due to a 
decreased serum albumin and poorly managed diarrhoea which are two known 
potential side effects of certain types of bariatric surgery. The problems with hepatic 
fibrosis are well known30 and are probably not related to the rate of weight loss but 
rather to surgically induced short bowel syndrome. Certainly, the issue of fibrosis did 
not figure in the clinical trials highlighted in this systematic review and such situations 
are not generally associated with the use of low-calorie diet or VLCD interventions.  
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Limited information was available regarding the response of renal function to weight 
loss induced by VLCD. Nevertheless, the current data suggest either an 
improvement or no change in response to weight loss induced by a VLCD followed 
by a weight maintenance period. Rolland et al12 suggest that improvements in renal 
function during a VLCD are possibly due to the associated increase in fluid intake 
and/or reduction in creatine intake.  
 
Obesity-related glomerular disease was first identified by Weisinger et al31 in the 
1970’s, and the prevalence of obesity-related glomerulopathy has been increasing as 
a consequence of the obesity epidemic.32 It has been suggested that reducing the 
glomerular hyperfiltration observed in the obese, may provide a way to prevent or 
delay the development of renal disease in these individuals.33 Indeed, Chagnac et 
al33 demonstrated improvements in GFR following weight loss induced by a 
gastroplasty. This was supported by the review by Navaneethan et al,34 where they 
reported that in patients with chronic kidney disease, bariatric surgery was 
associated with a decrease in BMI with resultant normalisation of glomerular 
hyperfiltration. They did, however, state that it remains to be clarified whether this 
normalisation resulted in long-term renal benefits. Rolland et al12 reported an 
improvement in eGFR following the VLCD.  The use of eGFR, however, is a poor 
indicator of improved renal function in this case.  As a direct result of the use of 
VLCDs, the intake of creatine drops dramatically and hence the serum creatinine 
also drops.  This may give a false impression of improved renal function. Also, the use 
of eGFR significantly underestimates measured kidney function with obesity, and measuring 
changes in eGFR when body surface area is also changing is problematic.35  
In addition,  the use of eGFR is not validated in patients with normal kidney function. 
 
Strengths and Limitations  
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The main limitation of this review is the small number of studies included as well as 
the lack of data presented in many of these. In addition, the heterogeneous nature in 
terms of study quality, treatment duration, outcomes measured and time points for 
these rendered it impossible to carry out a meta-analysis.  It is also important to 
highlight that only one study16 reported hepatic outcomes and none reported renal 
outcomes immediately post (or during active VLCD) compared with at follow-up (long 
after the VLCD was completed). 
 
Finally, in assessing kidney function outcomes, it would have been beneficial to have 
information about renal blood flow, arterial pressure and albuminuria.  
 
Conclusion 
There are currently no effective treatments for NAFLD other than weight reduction 
and lifestyle modification.36,37 The effect of VLCDs on hepatic and renal outcomes 
remain unclear at this stage. There have been a number of improvements observed 
in terms of hepatic and renal outcomes, however, there may be some concern about 
the onset of fibrosis in some individuals, although no evidence for this was observed 
in the current systematic review. Renal outcomes seem little affected by VLCDs, 
however the studies measuring kidney function included only adults with normal 
kidney function, and the results cannot be extrapolated to those with any degree of 
kidney disfunction.  At this stage, further standardised research is required to fully 
assess the impact of VLCDs on hepatic and renal health and to better advise clinical 
practice.  
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Figure 1: Summary of literature search 
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No liver/kidney outcomes (n = 11) 
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Table 1: Summary of studies included in the review. 
 
Author N 
(males) 
Study Mean BMI 
(kg/m2) 
 Inclusion 
Criteria 
Duration 
of VLCD 
Duration of 
follow up 
Weight (kg) at 
baseline 
Weight (kg)at 
the end of the 
VLCD period 
Weight (kg) at 
the end of the 
follow up 
Arai et 
al16 
45  
(12) 
 
 
RCT where patients 
undertook either  
1) Supplemental LCD  
(3515-5021kJ/d with use 
of 2-3 packages of Optifast 
70 and 2678-3682 kJ of 
conventional balanced 
meals consisting of a 
mixture of 88g P, 30-80g 
CHO, 4-9g F)  or 
 
2) VLCD where 
participants  used 5 
packages of Optifast 70 
(daily energy intake of 
1757kJ, 70g protein, 30g 
CHO, 2g F).  
 
 
 
SLCD:   
31.9 (4.4)  
 
 
 
 
 
 
 
VLCD: 
32.9 (6.1) 
 Overweight 
adult men and 
women 
8 weeks - SLCD:  
81.5 (14.0) 
 
 
VLCD: 
 82.0(20.0) 
 
 
SLCD: 
76.3 (14.7) a 
 
VLCD:  
73.0 (16.3) a 
 
- 
Doherty 
et al17 
26 
(0) 
RCT where patients 
received  either  
1) Control:  diet of their 
choosing throughout the 
45 weeks (Control);  
 
2) VLCD:  one week 
1200kcal/d BDD and a 
420kcal/d liquid diet for 
weeks 2-17. Patients were 
realimented during weeks 
18-24 increasing the daily 
caloric intake by ~ 
150kcal/wk until reached 
~1150kcal/d at week 24. 
Patients were instructed to 
consume a balanced diet 
providing 1200-1500kcal/d 
 
 
Control:  
33.4 (2) 
 
 
VLCD:  
40.4 (2) 
 
 
 
 
 
 
 
 
 
 
 Obese women  15 weeks 29 weeks Control:  
94.7 (5.0) 
 
VLCD: 
111.2 (5.0) 
 
BDD + exercise: 
102.8 (6) 
Control: 
 Δ 2.7 (1.2) 
 
VLCD: 
 Δ -21.3 (2.1) a,d 
 
BDD + exercise: 
 Δ -10.3 (2.7) a,d 
Control:  
Δ 3.9(2.3) 
 
VLCD:  
Δ -22.4 (3.4)a,d 
 
BDD + exercise:  
Δ -14.5 (5.5) a,d 
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for the remainder of the 
treatment (weeks 26-45).  
 
3) BDD + exercise: 
consume a BDD providing 
1000-1500 kcal/d (15-
20% protein; 50-55% 
CHO, 30% fat) for 45 
weeks. Instructed (at 
week 8) to begin a 
program of aerobic activity 
(mostly consisting of 
walking). Initially10-
20mins 2-3x/wk. By end of 
study, they reported 
exercising for 20-40mins 
3-5x/wk. 
 
 
 
 
BDD: 
36.5 (2) 
Hauner 
et al20 
110  
(22) 
RCT where patients 
underwent a pre-
treatment phase of 
VLCD/LCD (700-
1000kcal/d) to achieve a 
weight loss of at least 2.3 
BMI units. Afterwards, 
participants asked to 
maintain an individually 
tailored weight 
maintaining diet and were 
either prescribed a placebo 
or acarbose (treatment 
started with 50mg 
once/day and titrated up 
to a maximum of 100mg 
t.i.d. at weekly intervals.) 
 
Placebo: 
34.8 (2.2) 
 
Acarbose: 
34.7 (2.3) 
 Weight stable 
obese  subject 
with BMI 32-38 
kg/m2  
10-16 
weeks 
26 weeks Placebo:  
97.8 (13.0) 
 
Acarbose:  
97.7 (13.5) 
No values Placebo: Δ 
0.6kg 
 
Acarbose: 
weight stable 
(no values) 
Lin et al21 132  
(43) 
RCT where patients 
undertook a 2 week 
introduction phase where 
they consumed a 
1200kcal/d diet. This was 
followed by a 450kcal/d 
VLCD 450: 
34.4 (3.5) 
 
 
VLCD 800: 
34.1 (3.9) 
 Obese (BMI 
≥30kg/m2) 
Taiwanese 
between the 
ages of 18-65y  
10 weeks - 450kcal/d:  
92.5 (14.1) 
 
 
800kcal/d: 
92.1(15.6) 
450kcal/d: 
 Δ -8.37 (0.70) b 
 
 
800kcal/d: 
 Δ -8.42 (0.70) b 
- 
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VLCD or an 800kcal/d 
VLCD for 10 weeks. 
 
Melin et 
al11 
43 
(4) 
 
RCT where patients 
undertook a 25 day VLCD 
followed by hypocaloric 
diet.  Patients were 
divided into 2 groups. 
 
Group 1:intensive 
behaviour modification 
therapy every fortnight 
during the first year and 
six meetings in the second 
year 
 
Group 2: planned 
meetings every third 
month.   
 
 
 
 
 
 
 
Group 1: 
35.6 (4.5) 
 
 
 
 
 
Group 2: 
35.2 (4.6) 
 
 Men and 
women; 24-60 
years old; BMI 
35 kg/m2 (29-
48). 
25 days  2 years Group 1:  
99.8 (SE 5.5) 
 
 
Group 2: 
93.4 (SE 4.1) 
Group 1:  
Δ - 8.3 (SE 0.64) 
b 
 
 
Group 2: 
Δ -10.0 (SE 0.71) 
b 
 
 
Group 1: 
Δ - 6.8 (SE 
1.4)a 
 
 
Group 2: 
Δ -8.6 (SE 1.6)a 
 
Olsson et 
al18 
43  
(0) 
RCT where patients were 
assigned to a 6 week VLCD 
to achieve at least a 5% 
reduction in body weight 
after which they resumed 
habitual eating patterns 
except for lunch which was 
replaced by Nutrilett 
Intensive meal (111kcal) 
mixed with a control or a 
test emulsion. 
 
Control: 
28.3 (1.6) 
 
 
Emulsion: 
28.2 (1.4) 
 Female, 18- 60 
years with BMI 
26-31 kg/m2  
6 weeks 12 weeks Control: 79.0 
(8.3) 
 
Test emulsion: 
79.7 (6.1)  
Control:  
71.5 (7.1)a 
 
Test emulsion: 
73.0 (5.3)a 
Control:70.2 
(6.9)a 
 
Test emulsion: 
72.0 (5.6)a 
Rolland 
et al12 
120 
(11) 
 
RCT where patients were 
assigned to a 600 calorie 
deficit diet for 3 months. 
Those who did not achieve 
a 5% were randomised to 
either: LCHP or VLCD for 
the following 9 months. 
 
LCHP: 
41.6 (4.8) 
 
VLCD: 
46.0 (7.0) 
 Men and 
women; >18 
years old; BMI 
≥35kg/m2 
6.9 
months (4-
9 months) 
- LCHP: 
110.4 (12.2) 
 
VLCD: 
129.6 (23.0) 
- LCHP: 
109.1 (14.6 ) 
 
VLCD: 
98.0 (20.3) c,e 
 
Ryttig 
and 
60  
(11) 
RCT where patients were 
assigned to 12 weeks of 
 
 
 Obese men and 
women 
12 weeks 52 weeks Solid food: 120.1 
(22.5)e  
Solid food:  
97.6 (19.1)a,d 
No significant 
change during 
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Rössner19 VLCD followed by a 
gradual increase of normal 
food during 1 week. After 
transition, patients were 
assigned to either:  
 
Group 1: normal, well-
balanced hypocaloric diet 
containing 1600kcal/d of 
which 220kcal was 
provided by two sachets of 
the Cambridge diet 
 
Group 2: normal, well-
balanced hypocaloric diet 
containing 1600kcal/d of 
solid food only.  
 
 
 
 
 
 
Group 1: 
38.0 (4.9) 
 
 
 
 
 
Group 2: 
40.3 (6.0) 
(BMI≥30 
kg/m2), 
between 19-
65y, with stable 
body weight 
within the last 2 
months (less 
than 3kg 
fluctuation) 
 
Meal 
replacement: 
108.1 (15.8) 
 
 
 
 
Meal 
replacement: 
85.7 (14.7) a 
the weight 
maintenance 
period between 
the groups (no 
values provided) 
Abbreviations: BDD –balanced deficient diet; BMI – body mass index; CHO – carbohydrate; LCD – low calorie diet; LCHP – low carbohydrate high protein; 
RCT – randomised controlled trial; t.i.d – three times daily; SE – standard error; SLCD- supplemental low calorie diet;  VLCD – very low calorie diet. 
Values are reported as means with standard deviations in brackets unless stated otherwise 
Δ represents a change 
a - p<0.05 from baseline 
b- p<0.001 from baseline 
c - p<0.0001 from baseline 
d - p<0.05 between groups 
e- p<0.001 between groups 
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Table 2: Quality assessment of included RCTs. 
 
 Quality of 
random 
allocation 
concealment 
Description 
of 
withdrawals 
and 
dropouts 
Intention 
to treat? 
Participants 
blinded to 
treatment 
status? 
Healthcare 
providers 
‘blind’ to 
treatment 
status? 
 
Outcome 
assessors 
blinded 
to 
treatment 
status? 
       
Arai et al16 B (I) C B C B (I) B (I) 
Doherty et 
al17 
B (I) C B C B (I) B (I) 
Hauner et 
al20 
B (I) A A A(II) A (II) B (I) 
Lin et al21 B (II) B (I) A C B (I) B (I) 
Melin et al11 B (I) A C C B (I) B (I) 
Olsson et 
al18 
B (I) A C A(II) A(II) B (I) 
Rolland et 
al12 
B (I) B (I) A C B (I) B (I) 
Ryttig and 
Rössner19 
B (I) A B C B (I) B (I) 
       
 
A - low risk of bias (A); B - unclear risk of bias; C - high risk of bias. 
Subset “I” suggests that a description was provided while subset “II” suggests that no description was provided. 
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Abbreviations: ALT – alanine aminotransferase; ALKP – alkaline phosphatase; AST – aspartate transaminase ,  GGT – gamma-glutamyl transpeptidase; LCD 
– low calorie diet; LCHP – low carbohydrate, high protein diet; SLCD – supplemental; VLCD – very low calorie diet; 
 
Values are reported as means  
Δ represents a change 
a - p<0.05 from baseline 
b - p<0.05 between groups 
c- likely to be significantly different from baseline, but no p value provided 
Table 3:  Summary of liver results.    
  AST (IU/L) ALT (IU/L) ALKP (IU/L) GGT (IU/L) Total bilirubin (mol/L) 
 
Albumin (g/L) 
Author Patient Groups Pre 
Post 
VLCD 
Study 
end Pre 
Post 
VLCD 
Study 
end Pre 
Post 
VLCD 
Study 
end Pre 
Post 
VLCD Study end Pre 
Post 
VLCD 
Study 
end Pre 
Post 
VLCD 
Study 
end 
Arai  
et al16 
SLCD 
 
VLCD 
 
26.3 
(24.5) 
 
22.9 
(18.3) 
16.0 
(6.4)c 
 
12.6 
(4.7) c 
- 
35.2 
(39.5) 
 
27.6 
(20.7) 
13.0 
(8.3)c 
 
14.1 
(9.8)c 
- - - - - - - 
      
Melin et 
al11 
 
 
 
Group 1: 
intensive 
 
Group2: 
less 
intensive  
 
 
 
29.4 
(5.9) 
 
29.4 
(5.9) 
-  No Δ 
29.4 
(11.8) 
 
29.4 
(11.8) 
- No Δ - - - 
30.0 
(24.0) 
 
24.0 
(12.0) 
- No Δ 
      
Rolland et 
al12 
 
 
VLCD 
 
 
LCHP 
- 
 
 
- 
- 
 
 
- 
- 
 
 
- 
30. 0 
(17.8) 
 
35.4 
(23.0) 
- 
 
 
- 
23.2 
(8.9)a,b 
 
34.5 
(27.7) 
81.6 
(19.6) 
 
89.1 
(32.9) 
- 
 
 
- 
77.3 
(23.0)a 
 
84.6 
(26.7) 
33.8 
(33.7) 
 
48.2 
(77.4) 
- 
 
 
- 
 
24.1 
(17.7)a,b 
 
 
39.6 (51.2) 
 
 
9.1 
(5.8) 
 
 
10.0 
(3.6) 
 
 
- 
 
 
- 
 
 
9.8 (7.3) 
 
 
9.4 
(5.1)a 
 
 
43.0 
(2.5) 
 
 
45.0 
(2.4) 
 
 
- 
 
 
 
- 
 
 
42.8 
(2.2)a 
 
 
45.6 
(5.8) 
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Table 4: Results of kidney (renal) results 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Abbreviations: eGFR – estimated glomerular filtration rate; LCHP – low carbohydrate, high protein diet; LL – LighterLife; VLCD – very low calorie diet; 
 
Values are reported as means  
 
a - p<0.05 from baseline 
b - p<0.05 between groups 
 
  Creatinine (µmol/L) eGFR (mL/min) Urea (mmol/L) 
Author Patient Groups Pre 
Post 
VLCD Study end Pre 
Post 
VLCD Study end Pre 
Post 
VLCD Study end 
Rolland et 
al12 
 
 
 
LL 
 
LCHP 
82.6 (9.2) 
 
82.1 (9.6) 
- 
 
- 
79.8 (6.6)a 
 
83.1 (11.6) 
77.1 (11.6) 
 
74.0 (11.0) 
- 
 
- 
79.7 (11.4)a,b 
 
73.1 (12.3) 
4.5 (1.0) 
 
4.7 (1.4) 
- 
 
- 
4.3    (1.1)a 
 
5.2    (1.4)a 
